EpiCast Report: Glaucoma-Epidemiology Forecast to 2023
Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye's optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), secondary glaucoma, and congenital glaucoma. Other less common types of glaucoma include normal-tension glaucoma (NTG), pseudoexfoliation glaucoma, and pigmentary glaucoma (NEI, 2014b). Although there are many types of glaucoma, the two most important types are OAG and ACG, with OAG accounting for about 80-90% of all glaucoma cases (Mayo Clinic, 2014). OAG and ACG can be primary (primary open-angle glaucoma [POAG] and primary angle-closure glaucoma [PACG], respectively) or secondary, depending on the cause.
GlobalData epidemiologists forecast that the total prevalent cases of glaucoma in the 7MM will grow by 14.60% over the next decade, from 13,748,430 total prevalent cases in 2013 to 15,761,674 total prevalent cases in 2023, with almost 60% of the total prevalent cases occurring in the US and Japan together.
The increase in the number of total prevalent cases of glaucoma in the 7MM can be attributed to changing population demographics in the respective markets. However, further epidemiological research is warranted given that there is a paucity of national and international data evaluating the prevalence and trends of glaucoma worldwide. There is also a need to clearly demarcate the glaucoma population in each clinical type, as currently available epidemiological literature fails to clearly demarcate different glaucoma populations.
The Glaucoma EpiCast Report provides an overview of the risk factors and global trends of glaucoma in the 7MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of total prevalent cases of glaucoma segmented by age (in five-year increments beginning at age 40), sex, clinical type (POAG, PACG, secondary glaucoma, and congenital glaucoma the total prevalent cases of NTG, which is a sub-type of OAG; and the diagnosed prevalent cases of POAG and PACG in these markets.
The glaucoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons To Buy
Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.
Identify the percentage of glaucoma prevalent cases by clinical type.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 13
3.3.1 US 13
3.3.2 5EU 14
3.3.3 Japan 15
3.4 Forecast Methodology 16
3.4.1 Sources Used 18
3.4.2 Forecast Assumptions and Methods 22
3.4.3 Sources Not Used 28
3.5 Epidemiological Forecast for Glaucoma (2013-2023) 29
3.5.1 Total Prevalent Cases of Glaucoma 29
3.5.2 Age-Specific Total Prevalent Cases of Glaucoma 30
3.5.3 Sex-Specific Total Prevalent Cases of Glaucoma 32
3.5.4 Age-Standardized Total Prevalence of Glaucoma 34
3.5.5 Total Prevalent Cases of Glaucoma, by Clinical Type 35
3.5.6 Total Prevalent Cases of NTG 37
3.5.7 Diagnosed Prevalent Cases of POAG and PACG 39
3.6 Discussion 42
3.6.1 Epidemiological Forecast Insight 42
3.6.2 Limitations of the Analysis 43
3.6.3 Strengths of the Analysis 44
4 Appendix 45
4.1 Bibliography 45
4.2 About the Authors 48
4.2.1 Epidemiologists 48
4.2.2 Reviewers 48
4.2.3 Global Director of Therapy Analysis and Epidemiology 49
4.2.4 Global Head of Healthcare 50
4.3 About GlobalData 51
4.4 About EpiCast 51
4.5 Disclaimer 51
1.2 List of Figures
Figure 1: 7MM, Total Prevalent Cases of Glaucoma, Ages ?40 Years, Both Sexes, N, 2013-2023 30
Figure 2: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N, 2013-2023 32
Figure 3: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ?40 Years, N, 2013 34
Figure 4: 7MM, Age-Standardized Total Prevalence of Glaucoma, by Sex, Ages ?40 Years, %, 2013 35
Figure 5: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ?40 Years, N, 2013 37
Figure 6: 7MM, Total Prevalent Cases of NTG, Ages ?40 Years, Both Sexes, N, 2013-2023 38
Figure 7: 7MM, Diagnosed Prevalent Cases of POAG, Ages ?40 Years, Both Sexes, N, 2013-2023 40
Figure 8: 7MM, Diagnosed Prevalent Cases of PACG, Ages ?40 Years, Both Sexes, N, 2013-2023 41
1.1 List of Tables
Table 1: Types of Glaucoma 10
Table 2: Risk Factors and Comorbidities for Glaucoma 12
Table 3: 7MM, Sources of Glaucoma Total Prevalence Data Used in the Epidemiology Forecast 17
Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of Glaucoma Segmented by Clinical Types 18
Table 5: 7MM, Sources Not Used in the Epidemiological Analysis of Glaucoma 28
Table 6: 7MM, Total Prevalent Cases of Glaucoma, Ages ?40 Years, Both Sexes, N, 2013-2023 29
Table 7: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N (Row %), 2013 31
Table 8: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ?40 Years, N (Row %), 2013 33
Table 9: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ?40 Years, N (Row %), 2013 36
Table 10: 7MM, Total Prevalent Cases of NTG, Ages ?40 Years, Both Sexes, N, 2013-2023 38
Table 11: 7MM, Diagnosed Prevalent Cases of POAG, Ages ?40 Years, Both Sexes, N, 2013-2023 39
Table 12: 7MM, Diagnosed Prevalent Cases of PACG, Ages ?40 Years, Both Sexes, N, 2013-2023 41
Single User License:
Corporate User License:
select a license
NEWSLETTER BY CATEGORY
The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"
This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"
I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"
While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"
We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"